Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX

被引：0

作者：

Nicola Silvestris

Anna Elisabetta Brunetti

Marco Russano

Patrizia Nardulli

机构：

[1] National Cancer Institute “Giovanni Paolo II”,Medical Oncology Unit

[2] National Cancer Institute “Giovanni Paolo II”,Scientific Direction

[3] University Campus Biomedico,Medical Oncology Unit

[4] National Cancer Institute “Giovanni Paolo II”,Pharmacy Department

来源：

Supportive Care in Cancer | 2013年 / 21卷

关键词：

Irinotecan; Oxaliplatin; Ondansetron; Granisetron; Aprepitant;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：2955 / 2956

页数：1

共 8 条

[1]

Conroy T(2011)FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 1817-1825

[2]

Desseigne F(2005)Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials Cancer 104 864-868

[3]

Ychou M(2003)Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America Cancer 97 3090-3098

[4]

Gralla RJ(undefined)undefined undefined undefined undefined-undefined

[5]

de Wit R(undefined)undefined undefined undefined undefined-undefined

[6]

Herrstedt J(undefined)undefined undefined undefined undefined-undefined

[7]

Poli-Bigelli S(undefined)undefined undefined undefined undefined-undefined

[8]

Rodrigues-Pereira J(undefined)undefined undefined undefined undefined-undefined

← 1 →